Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalantercept plus Sorafenib in Advanced Hepatocellular Carcinoma
NCT02024087Phase 2Completed
- Start
- Aug 2014
- Primary completion
- Jul 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of dalantercept in hepatocellular carcinoma (HCC). Started Aug 2014; status: completed.
02
Drugs
dalantercept
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02024087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024087.